



Exploring biomarkers and transcriptional factors in type 2 diabetes by comprehensive bioinformatics analysis on RNA-Seq and scRNA-Seq data

Yalan Huang^{1#}, Linkun Cai^{2#}, Xiu Liu³, Yongjun Wu⁴, Qin Xiang⁵, Rong Yu¹

¹College of Graduate, Hunan University of Traditional Chinese Medicine, Changsha, China; ²Department of Gastroenterology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China; ³College of Traditional Chinese Medicine, Hunan University of Traditional Chinese Medicine, Changsha, China; ⁴College of Pharmacy, Hunan University of Traditional Chinese Medicine, Changsha, China; ⁵Science and Technology Department, Hunan University of Traditional Chinese Medicine, Changsha, China

Contributions: (I) Conception and design: Y Huang, L Cai, Q Xiang, R Yu; (II) Administrative support: Y Huang, L Cai, X Liu; (III) Provision of study materials or patients: Y Huang, L Cai, Y Wu; (IV) Collection and assembly of data: Y Huang, L Cai, Q Xiang; (V) Data analysis and interpretation: Y Huang, L Cai, R Yu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Rong Yu; Qin Xiang. Hunan University of Traditional Chinese Medicine, Changsha, China.

Email: yurong8072@qq.com; 003852@hnucm.edu.cn.

Background: Type 2 diabetes (T2D) is a prevalent chronic disease with elusive. Combining transcriptome and single-cell sequencing data to explore biomarkers of T2D could provide new insights into the in-depth understanding of the molecular mechanisms and diagnosis of T2D.

Methods: The GSE41762 dataset including RNA-seq data for healthy and T2D patients, was obtained from the Gene Expression Omnibus (GEO) database. The potential functions of the differentially expressed genes (DEGs) were revealed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Moreover, biomarkers were screened out by the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm and receiver operating characteristic (ROC) analysis. Furthermore, single-cell RNA (sc-RNA)-seq data in the “E-MTAB-5061” dataset was downloaded from the ArrayExpress (European Bioinformatics Institute, EBI) database. Principal components analysis (PCA) and t-distributed stochastic neighbor embedding (tSNE) were used for dimensionality reduction analysis and cell clustering. The FindAllMarkers function was used to annotate different cell clusters, and key cell clusters were screened by the expression levels of the biomarkers. Finally, the transcription factors (TFs) of the biomarkers were recognized.

Results: A total of 111 DEGs were screened in the GSE41762 dataset, which were mainly related to hormone secretion, specialized postsynaptic membrane, pancreatic secretion, JAK-STAT signaling pathway, and Ras signaling pathway. In addition, *SLC2A2*, *SERPINF1*, *RASGRP1*, and *CHL1* were screened out as biomarkers of T2D, which possessed potential diagnostic value as AUC value greater than 0.8. A total of 1,515 T2D group cells and 1,817 healthy cohort cells were screened as core cells in the “E-MTAB-5061” dataset. Following tSNE dimensionality reduction cluster analysis, the core cells were divided into 13 cell clusters. According to the marker genes, the 13 cell clusters were annotated into six types of cells. Notably, *SERPINF1* was highly expressed in fibroblasts and might be regulated by *NR2F2* (nuclear receptor subfamily2, group F, and member 2).

Conclusions: This study identified four biomarkers (*SLC2A2*, *SERPINF1*, *RASGRP1*, and *CHL1*) for T2D, which provided new markers for the clinical diagnosis of T2D. Among them, *SERPINF1* might be regulated by *NR2F2*, which provides valuable insight into the pathogenesis of T2D.

Keywords: Type 2 diabetes (T2D); RNA-seq; single-cell RNA (sc-RNA)-seq; biomarkers; transcription factors (TFs)

Submitted Jul 22, 2022. Accepted for publication Sep 21, 2022.

doi: 10.21037/atm-22-4303

View this article at: <https://dx.doi.org/10.21037/atm-22-4303>

Introduction

Diabetes mellitus (DM) is a chronic disease characterized by high blood sugar levels, caused by insufficient insulin production by the pancreas or an inappropriate response of the body's cells to insulin (1). DM is generally classified into two forms: type 1 diabetes (T1D) and type 2 diabetes (T2D). Of these, T2D is the most common type of diabetes, accounting for 90–95% of all diabetes cases, and is primarily characterized by pancreatic beta-cell dysfunction and insulin resistance (2). T2D can lead to serious clinical complications such as diabetic cardiomyopathy, retinopathy, nephropathy, and neuropathy, with high rates of disability and mortality (3). As lifestyle habits have changed, the number of T2D patients globally has increased significantly. According to the World Health Organization (WHO), T2D affected 425 million people worldwide in 2017 and is expected to affect 629 million people by 2045 (4). At present, clinically, the early diagnosis of T2D lacks reliable biomarkers, and its pathogenesis has not been fully studied, and the treatment is still challenging (5). Although some glycemic control drugs are used to treat advanced T2D, complete remission is rare among patients (6). Therefore, the study of early diagnostic markers and molecular pathology of T2D is of great significance for the clinical treatment of T2D.

RNA-sequencing (RNA-seq) is a precise and sensitive technique for examining global gene expression profiles (7), providing new and powerful means to study the pathogenesis of complex diseases such as T2D (8). In the past, studies have tried to find the biomarker genes of T2D through RNA-seq, and proposed the possible molecular mechanism. Che *et al.* proposed that 10 hub genes including *CNOT6L*, and *CNOT6*, etc, are involved in the pathogenesis of T2D (9). Transcriptomic analysis also found that two core genes, *SERPINF1* and *ANPEP*, were associated with the development of T2D (10). Whether these genes can work as clinical biomarkers of T2D, there is a lack of modeling verification of large-scale clinical samples. In addition, a limitation of RNA-seq methods is that bulk RNA-seq cannot capture the heterogeneity of each sample (11). Furthermore, heterogeneity may exist even within a single disease (12). Single-cell RNA sequencing

(scRNA-seq) is a new technology to reveal cellular heterogeneity, which not only overcomes the limitations of traditional RNA-sequencing techniques in detecting small expression differences between cells (13), but also clearly shows gene expression profiles of various cell types, as well as specific cellular functional alterations.

In this study, we obtained RNA-seq data from healthy and T2D patient cohorts from the Gene Expression Omnibus (GEO) database. Subsequently, we performed Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment pathway analysis to explore the biological functions and enrichment pathways of differentially expressed genes (DEGs). Importantly, we also applied the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm and Nomogram establishment, demonstrating that *SLC2A2*, *SERPINF1*, *RASGRP1* and *CHL1* are reliable biomarkers of T2D. Finally, we annotated cell clusters by analyzing single-cell sequencing data of human islet cells, and screened key cell clusters using biomarker expression levels, and finally identified biomarker transcription factors (TFs). Our findings suggest that aberrantly expressed *SERPINF1* in fibroblasts may be regulated by *NR2F2*, which provides new insights into the treatment of T2D. We present the following article in accordance with the TRIPOD reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-4303/rc>).

Methods

Data source

We downloaded the GSE41762 dataset containing RNA-seq data from the islet tissues of 57 healthy participants and 20 T2D patients from the GEO database (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41762>). Moreover, the scRNA-seq data of pancreatic tissue and islets of six healthy controls and four T2D donors was downloaded from the ArrayExpress database (registration number: “E-MTAB-5061”) (<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5061/>). The design and analysis flow of this study was shown in Figure S1. The study was

conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Differential expression analysis

The “limma” R package (<https://bioconductor.org/packages/release/bioc/html/limma.html>) was applied to screen DEGs between the healthy and T2D samples with a setting of $|\log_2 \text{fold change (FC)}| > 0.5$ and $P < 0.05$ (14). Next, the volcano plot of DEGs was displayed using the “ggplot2” R package, and the heatmap of DEGs was plotted using the “heatmap” R package.

Functional enrichment analysis

The “clusterProfiler” package in R language was used to perform the GO and KEGG enrichment analyses of DEGs (15). $P < 0.05$ was considered to indicate significant enrichment.

Biomarkers screening

The LASSO algorithm in R language was used to screen biomarkers for T2D. Next, the ability of biomarkers to distinguish healthy from T2D patients was analyzed using receiver operating characteristic (ROC) curves of the “pROC” package by calculating the area under curve (AUC) values of the ROC curves. Genes with AUC values greater than 0.8 were defined as biomarkers.

Nomogram establishment

A nomogram based on the biomarkers was constructed using the “lrm” function in the R package to predict the probability of illness. Moreover, calibration curves were displayed using the “rms” package, decision curves were constructed by “ggDCA” package and ROC curves were applied to verify the validity of the nomogram.

Single-cell analysis

The “Seurat” R package was utilized to process the scRNA-seq data. The data were initially filtered according to the following criteria: (I) genes that were only expressed in ≤ 3 cells; (II) low-quality cells with < 100 genes; and (III) cells with $> 10,000$ genes. Next, the retained cells were defined as core cells. Moreover, analysis of variance (ANOVA) as performed on the genes of core cells to screen out the

highly variable genes (16). Moreover, the gene expression of core cells was normalized through a linear regression model, and principal components analysis (PCA) was performed to illustrate the distribution of core cells. Next, the top 20 principal components were selected for data dimensionality reduction using the tSNE algorithm in the R language. The “FindAllMarker” function of the “Seurat” R package was employed to identify marker genes and used these marker genes to annotate different cell clusters through the R package “single” and “CellMarker” database (17). Also, the expression levels of biomarkers were utilized to screen the key cell clusters.

The fibroblasts were separated into high and low expression groups according to the expression of biomarkers. Gene set variation analysis (GSVA) was used to analyze the functional enrichment of all genes in the biomarker genome. Differences in the GSVA scores (which we denoted as “ τ ”) between the high and low biomarker expression groups were analyzed using the “limma” R package (18).

SCENIC analysis

Single-cell regulatory network inference and clustering (SCENIC) analysis was performed on the high and low biomarker expression groups using the “SCENIC” package in R language to identify the TFs (19).

Statistical analysis

All analyses were conducted using the R programming language. If not specified above, a P value (two-sided) less than 0.05 was considered statistically significant.

Results

Analysis of T2D-related DEGs

Following analysis using the “limma” package, a total of 111 DEGs between the control and T2D groups were obtained, including 68 up-regulated genes and 43 down-regulated genes (*Figure 1A, 1B*, <https://cdn.amegroups.cn/static/public/atm-22-4303-1.xls>). The GO analysis results showed that 111 genes were enriched, with a total of 636 GO terms, including the regulation of hormone secretion, positive regulation of the MAPK (mitogen activated protein kinase) cascade, metabolic process of collagen, *etc.* (*Figure 2A*, <https://cdn.amegroups.cn/static/public/atm->




Figure 1 The volcano plot (A) and heatmap (B) of differentially expressed genes.




Figure 2 GO (A) and KEGG (B) functional analysis of the differentially expressed genes. BP, biological process; CC, cell component; MF, molecular function; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; EGFR, epidermal growth factor receptor.




Figure 3 LASSO regression analysis (A and B) and univariate Cox regression (C) analysis were used to screen eigengenes. LASSO, least absolute shrinkage and selection operator, the basic idea of LASSO is to minimize the residual sum of squares under the constraint that the sum of the absolute values of the regression coefficients is less than a constant, so as to produce some regression coefficients strictly equal to 0 to get an interpretable model.

22-4303-2.xls). In addition, these DEGs were involved in diabetes at maturity, pancreatic secretion, the Ras signaling pathway, *etc.* (Figure 2B, <https://cdn.amegroups.cn/static/public/atm-22-4303-3.xls>).

Identification of biomarkers

To further screen out the biomarkers in T2D, the LASSO algorithm was executed based on the 111 DEGs. Based on $\lambda_{\min} = 0.1169$, a total of six genes were extracted, namely *SLC2A2*, *SERPINF1*, *RASGRP1*, *CHL1*, *PGC*, and *IAPP* (Figure 3A,3B, <https://cdn.amegroups.cn/static/public/atm-22-4303-4.xls>).

The gene with the highest AUC value was *SLC2A2* (AUC =0.9), followed by those of *SERPINF1*, *RASGRP1*, and *CHL1* (AUC =0.83), and the AUCs of *PGC* and *IAPP* were 0.79 and 0.77, respectively. Notably, *SLC2A2*, *SERPINF1*, *RASGRP1*, and *CHL1*, which had AUCs >0.8, were screened as biomarkers for subsequent analysis (Figure 3C).

Nomogram construction

A nomogram based on *SLC2A2*, *SERPINF1*, *RASGRP1*, and *CHL1* was constructed (Figure 4A), and the calibration curve indicated that the diagnostic model nomogram was effective (Figure 4B). The highest benefit rate of the model (*SLC2A2* + *SERPINF1* + *RASGRP1* + *CHL1*) highlighted the validity of the nomogram (Figure 4C). Furthermore, the AUC value of the nomogram based on *SLC2A2* +

SERPINF1 + *RASGRP1* + *CHL1* was 0.902, which verified the effectiveness of the nomogram (Figure 4D).

Screening of single-cell data and cell cluster analysis

After filtering, a total of 1,515 and 1,817 cells were retained in the T2D and healthy groups, respectively (Figure 5A). These cells were computed by ANOVA and the top 2,000 most variable genes were selected (Figure 5B).

Following the normalization of gene expression, PCA of the variably expressed genes between the T2D and healthy groups was conducted (Figure 5C), and the top 20 principal components were screened for subsequent analysis (Figure 5D,5E).

Through unbiased clustering based on the tSNE analyses, 13 cell clusters were identified (Figure 6A). The results of cell cluster analysis in the healthy and T2D cohorts are shown in Figure 6B. Marker genes were screened using the FindAllMarkers function (<https://cdn.amegroups.cn/static/public/atm-22-4303-5.xls>) and the top five marker genes are displayed in Figure 6C.

Based on the marker genes, we annotated 13 cell clusters to six different cell types (Figure S2A), including epithelial cells (CELA3A, CTRB1, SPINK1, CLPS, PRSS3, and eGFP), fibroblasts (BGN, SFRP2, COL3A1, COL1A2, IGFBP4, and SPARC), neurons (GPC5-AS1, DLK1, STMN2, SEC11C, G6PC2 and LY6E), endothelial cells (CLDN5, RGCC, IFI27, CD36, PLVAP, and ESAM), macrophages (ALOX5AP, CPA3, S100A4, TPSB2,




Figure 4 The nomogram of diagnostic markers (A); calibration curve for the nomogram model (B); decision curve analysis (C); ROC curve analysis of the diagnostic model (D). AUC, area under curve; ROC, receiver operating characteristic; DCA, decision curve analysis.

TPSAB1, and TPSD1), and hepatocytes (CRYBA2, TTR, GPX3, CHGA, SNORD50A, and GCG). The expression levels of marker genes in the six cell types were displayed in violin and scatter plots (Figure S2B-S2M).

Confirmation of the key cell clusters and GSEA analysis

We found that *SERPINF1* was mainly expressed in fibroblasts, which indicated that fibroblasts may be more correlated with the occurrence and progression of diabetes, so fibroblasts were used as the target cell for subsequent analysis (Figure S3A,S3B). The expression

level of *SERPINF1* in fibroblasts in the healthy group was higher than that in fibroblasts in the T2D group (Figure S3C, S3D). Furthermore, we discovered that the proportion of fibroblasts with a high expression of *SERPINF1* was higher in the healthy group than in the T2D group (Figure S3E).

To explore the potential role of fibroblasts with high and low expressions in T2D, we analyzed the foundational enrichment by GSEA. Seventeen functional pathways were mainly activated in the high expression group, including phosphatidylinositol-3 kinase/protein kinase B (PI3K-AKT) signaling, interferon α response, reactive oxygen species




Figure 5 Single-cell data filtering, the left ordinate represents the number of genes, and the right ordinate represents the count value of gene expression (A); display of hypervariable genes (B); PCA (C); principal component screening (D and E). PCA, principal component analysis.

pathway, and 21 functional pathways including apoptosis, inflammatory response pathway, and myogenesis were activated in the low expression group (Figure 7, <https://cdn.amegroups.cn/static/public/atm-22-4303-6.xls>).

Analysis of key TFs and target genes

To investigate the specific transcriptional regulators of fibroblasts with high and low expressions of *SERPINF1*, the TFs of the two cell groups were predicted by *SCENIC*, and the top 10 TFs of relative activity scores were demonstrated in Figure 8A and Figure 8B (<https://cdn.amegroups.cn/static/public/atm-22-4303-7.xls>). Both cell groups were regulated by *HEYL*, *HOXB2*, *HOXA1*, *ATF5*, *ZNF467*, *SMARCB1*, *CREB3L1*, *JUNB*, and *NR1H2*, which have

already been identified as TFs for fibroblasts. However, *NR2F2* and *NFE2L2* were specific TFs in the high and low biomarker expression groups, respectively (Figure 8C), and their expression levels were visualized in Figure 8D, 8E. The expression level of *NR2F2* was significantly different, and therefore, it was considered as a TF of fibroblasts with high *SERPINF1* expression (Figure 8F).

We also extracted the target genes regulated by *NR2F2* from the *SCENIC* analysis results and intersected them with the DEGs. A total of 18 genes were both target genes and DEGs (Figure 8G), and four target genes: *SERPINF1*, *SFRP4*, *CELA3A*, and *CTRC* had notable differences between the fibroblasts with high and low expressions of *SERPINF1* (Figure 8H), and their expression levels are displayed in Figure 8I, 8J.




Figure 6 The results of the tSNE analysis (A); display of clustering results in different groups (B); heatmap display of top5 marker genes in different subclusters (C). tSNE, t-distributed stochastic neighbor embedding. T2D, type 2 diabetes.

Discussion

Diabetes is an incurable chronic disease with chronic complications that can spread to vital organs of the body, and severe acute complications can be life-threatening. T2D accounts for more than 90% of the total number of diabetic patients (20). At present, the pathogenesis of T2D has not been fully studied, and in-depth research will help to advance the problem of curing T2D. With the development of single-cell sequencing technology, scRNA-seq data analysis has become a current research hotspot. Unlike tissue expression data, scRNA-seq data can mask

important transcriptional signals contained in individual cells, and researchers can study genes at higher resolution in different types of cell populations based on scRNA-seq data (21). Using scRNA-seq data to study the gene expression profile changes and pathogenesis of T2D is a promising and effective method.

To further screen the biomarkers in T2D, we applied the LASSO algorithm based on 111 DEGs and identified four biomarker genes, including *SLC2A2*, *SERPINF1*, *RASGRP1*, and *CHL1*. These four genes have been studied in the past, including those linked to diabetes. In mice, biallelic *SLC2A2* inactivation induces neonatal




Figure 7 GSVA enrichment analysis. GSVA, Gene set variation analysis.

diabetes (22) and biallelic *SLC2A2* mutations cause Fanconi-Bickel syndrome (FBS).


A previous study investigated the role of *SLC2A2* in transient neonatal diabetes mellitus (TNDM) or permanent neonatal diabetes mellitus (PNDM) using a combination of sequencing and homozygosity mapping to rule out common genetic causes of NDM. Of the 104 included patients, five had *SLC2A2* homozygous mutations, including four *de novo* mutations. Four out of five patients with *SLC2A2* mutations developed isolated diabetes followed by Fanconi-Bickel syndrome. Four out of five patients had TNDM, and one patient with PNDM was still on insulin at 28 months. These results suggest that *SLC2A2* mutation is an autosomal recessive cause of NDM. Patients with homozygous *SLC2A2* mutations may have neonatal diabetes, which emphasizes the role of GLUT2 in human beta cells (23).

Pigment epithelium-derived factor (PEDF), also known as serpin F1 (human gene symbol: *SERPINF1*), belongs to the serpin family of peptide enzyme inhibitors. *SERPINF1* exerts multiple roles *in vitro* and in mice, including promoting neuronal survival and differentiation and effectively inhibiting angiogenesis (24). The fat mass-increasing allele SNP rs12603825 is significantly associated with increased fasting *SERPINF1* concentrations, and

SERPINF1 levels are significantly positively correlated with all of the measured body fat parameters and fasting leptin concentrations. A common functional genetic variant at the locus encoding *SERPINF1* is associated with overall obesity, obesity-related insulin resistance, and circulating leptin levels in populations that are at increased risk of T2D (25). Impaired endothelial angiogenesis is a hallmark of diabetic vascular complications.

RASGRP1, a member of the RasGRP family, is a nucleotide exchange factor necessary for Ras activation, which in turn stimulates various effector systems (26,27). A study has shown that knockdown of *RasGRP1* significantly attenuates vascular endothelial growth factor (VEGF) induced migration and angiogenesis of human umbilical vein endothelial cells (HUVECs) and activation of the AKT pathway. Phosphorylation of *VEGF*, *RASGRP1*, and *AKT* is downregulated in high glucose-exposed HUVECs compared with normal glucose, whereas metformin up-regulates *RASGRP1*-dependent VEGF signaling and ameliorates impaired angiogenesis induced by high glucose. *RASGRP1* is also involved in VEGF-induced angiogenesis and the pro-angiogenic effect of metformin under hyperglycemia (28).

CHL1 is a neural recognition molecule of the immunoglobulin superfamily that is mainly expressed in the






Figure 8 *SERPINF1* overexpresses top10 transcription factor in Fibroblasts cells (A); *SERPINF1* low expression top10 transcription factor in Fibroblasts cells (B); transcription factor Venn diagram (C); violin plot of expression levels of different transcription factors (D); scatter plot of expression levels of different transcription factors (E); differences between high and low expression groups of transcription factor biomarkers (F); Venn diagram of specific transcription factor target genes (G); differential analysis of transcription factor target genes between high and low expression groups of biomarkers (H); violin plot of expression levels of transcription factor target genes (I); scatter plot of transcription factor target gene expression (J). *, $P < 0.05$, ****, $P < 0.0001$, ns, not significant. TF, transcription factor; GEO, Gene Expression Omnibus; DEG, differentially expressed gene.

nervous system (29). *CHL1* regulates neuronal migration, axonal growth, and dendritic projection. In contrast to *CHL1* overexpression, silencing of *CHL1* induces cell proliferation, decreased apoptosis, prolonged S phase, and shortened G1 phase of the cell cycle. Extracellular signal-regulated kinase (ERK) 1/2-MAPK inhibitors abolish the effect of *CHL1* deficiency on MIN6 cell proliferation. Furthermore, a high-fat diet results in increased islet volume and β -cell proliferation in mice, decreased *CHL1* expression, and activation of the ERK pathway. Thus, high fat-induced

decreased expression of *CHL1* in mouse islets leads to cell proliferation via the ERK pathway and regulation of the cell cycle via the p53 pathway. These mechanisms may contribute to obesity-induced compensatory hyperplasia of pancreatic beta cells in prediabetes (30).

In addition, we also investigated specific TFs that were differentially expressed in fibroblasts with high and low expressions of *SERPINF1*, and finally found that the TFs *NFE2L2* and *NR2F2* were differently expressed in fibroblasts with low and high expressions of *SERPINF1*,

respectively. *NFE2L2*, a member of the small family of basic leucine zipper (bZIP) proteins, exerts anti-oxidation and inflammation regulation functions (31). The high expression of *NR2F2* is more significant in fibroblasts with high *SERPINF1* expression, and its four target genes are differentially expressed in the two groups. *NR2F2* is a nuclear receptor family gene and a ligand-induced TF that can regulate multiple genes (32). *NR2F2* is thought to play a role in tumor progression and chronic periodontitis (33,34); however, the function of *NR2F2* in the pathogenesis of diabetes needs to be further studied.

Our study also has certain limitations that should be noted. The sample size of single-cell data is too small, and there is no clinical sample validation. Also, experiments allowing further functional studies on key genes, such as *NR2F2*, were lacking. However, our study provides new important clues for the study of the pathogenesis of diabetes and proposes a possible function of fibroblasts in T2D (35). We will also continue to monitor our research findings.

In conclusion, we performed scRNA-seq analysis of T2D in this study. T2D-related DEG analysis yielded a total of 111 DEGs. Then, based on the LASSO algorithm of these DEGs, we identified relevant biomarkers, including *SLC2A2*, *SERPINF1*, *RASGRP1*, and *CHL1*, which could be used for the biological diagnostic prediction of T2D. Single-cell data screening and cell clustering analysis revealed that 13 cell clusters were annotated into six different cell types, including epithelial cells, fibroblasts, neurons, endothelial cells, macrophages, and hepatocytes. Interestingly, we found that *SERPINF1* was predominantly expressed in fibroblasts, and subsequent analysis of fibroblasts revealed that *SERPINF1* was expressed at higher levels in healthy constitutive fibroblasts than in T2D constitutive fibroblasts. Analysis of the key TFs and target genes found that *NR2F2* and its target genes were differentially expressed in the two groups of fibroblasts, suggesting that *NR2F2* is involved in the pathogenesis of T2D. Further research will reveal the specific mechanism of *NR2F2* in T2D.

Acknowledgments

Funding: This work was supported by grants from the National Natural Science Foundation of China (No. 82074400), Hunan Provincial Technology Key Research and Development Program (No. 2020SK2101), National Natural Science Foundation of China (No. 82004185), Postgraduate Research and Innovation Project of Hunan Province (No. CX20210692), and Hunan Provincial Key

Laboratory of Translational Medicine for TCM Recipe and Syndrome Research (No. 2018TP1021).

Footnote

Reporting Checklist: The authors have completed the TRIPOD reporting checklist. Available at <https://atm.amegroupp.com/article/view/10.21037/atm-22-4303/rc>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroupp.com/article/view/10.21037/atm-22-4303/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Namayandeh SM, Karimi A, Fallahzadeh H, et al. The incidence rate of diabetes mellitus (type II) and its related risk factors: A 10-year longitudinal study of Yazd Healthy Heart Cohort (YHHC), Iran. *Diabetes Metab Syndr* 2019;13:1437-41.
2. Gheibi S, Singh T, da Cunha JPMCM, et al. Insulin/Glucose-Responsive Cells Derived from Induced Pluripotent Stem Cells: Disease Modeling and Treatment of Diabetes. *Cells* 2020;9:2465.
3. Chen YT, Lin WD, Liao WL, et al. NT5C2 methylation regulatory interplay between DNMT1 and insulin receptor in type 2 diabetes. *Sci Rep* 2020;10:16087.
4. Al Arawi WA, Al Shaman US, Albalawi WAM, et al. Association of Demographic Variables with the Awareness of Type 2 Diabetes Mellitus Patients (T2DM) among the

- Northwest Population in Saudi Arabia. *J Diabetes Res* 2020;2020:9408316.
5. Chen C, Xiang Q, Liu W, et al. Co-expression Network Revealed Roles of RNA m6A Methylation in Human β -Cell of Type 2 Diabetes Mellitus. *Front Cell Dev Biol* 2021;9:651142.
 6. Courtney H, Nayar R, Rajeswaran C, et al. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. *Diabetes Metab Syndr Obes* 2017;10:79-87.
 7. Kim C, Jeong SH, Kim J, et al. Evaluation of the effect of filtered ultrafine particulate matter on bleomycin-induced lung fibrosis in a rat model using computed tomography, histopathologic analysis, and RNA sequencing. *Sci Rep* 2021;11:22672.
 8. Afzal M, Alghamdi SS, Migdadi HH, et al. Legume genomics and transcriptomics: From classic breeding to modern technologies. *Saudi J Biol Sci* 2020;27:543-55.
 9. Che X, Zhao R, Xu H, et al. Differently Expressed Genes (DEGs) Relevant to Type 2 Diabetes Mellitus Identification and Pathway Analysis via Integrated Bioinformatics Analysis. *Med Sci Monit* 2019;25:9237-44.
 10. Ding L, Fan L, Xu X, et al. Identification of core genes and pathways in type 2 diabetes mellitus by bioinformatics analysis. *Mol Med Rep* 2019;20:2597-608.
 11. Anene CA, Taggart E, Harwood CA, et al. Decosus: An R Framework for Universal Integration of Cell Proportion Estimation Methods. *Front Genet* 2022;13:802838.
 12. Dacquino C, De Rossi P, Spalletta G. Schizophrenia and bipolar disorder: The road from similarities and clinical heterogeneity to neurobiological types. *Clin Chim Acta* 2015;449:49-59.
 13. Li RY, Guan J, Zhou S. Boosting scRNA-seq data clustering by cluster-aware feature weighting. *BMC Bioinformatics* 2021;22:130.
 14. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;43:e47.
 15. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innovation (Camb)* 2021;2:100141.
 16. Gribov A, Sill M, Lück S, et al. SEURAT: visual analytics for the integrated analysis of microarray data. *BMC Med Genomics* 2010;3:21.
 17. Zhang X, Lan Y, Xu J, et al. CellMarker: a manually curated resource of cell markers in human and mouse. *Nucleic Acids Res* 2019;47:D721-8.
 18. Hänzelmann S, Castelo R, Guinney J. GSEA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinformatics* 2013;14:7.
 19. Aibar S, González-Blas CB, Moerman T, et al. SCENIC: single-cell regulatory network inference and clustering. *Nat Methods* 2017;14:1083-6.
 20. Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. *Lancet Diabetes Endocrinol* 2021;9:525-44.
 21. Luecken MD, Theis FJ. Current best practices in single-cell RNA-seq analysis: a tutorial. *Mol Syst Biol* 2019;15:e8746.
 22. Thorens B, Cheng ZQ, Brown D, et al. Liver glucose transporter: a basolateral protein in hepatocytes and intestine and kidney cells. *Am J Physiol* 1990;259:C279-85.
 23. Sansbury FH, Flanagan SE, Houghton JA, et al. SLC2A2 mutations can cause neonatal diabetes, suggesting GLUT2 may have a role in human insulin secretion. *Diabetologia* 2012;55:2381-5.
 24. Becerra SP, Sagasti A, Spinella P, et al. Pigment epithelium-derived factor behaves like a noninhibitory serpin. Neurotrophic activity does not require the serpin reactive loop. *J Biol Chem* 1995;270:25992-9.
 25. Böhm A, Ordelleide AM, Machann J, et al. Common genetic variation in the SERPINF1 locus determines overall adiposity, obesity-related insulin resistance, and circulating leptin levels. *PLoS One* 2012;7:e34035.
 26. Ebinu JO, Bottorff DA, Chan EY, et al. RasGRP, a Ras guanyl nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. *Science* 1998;280:1082-6.
 27. Yamashita S, Mochizuki N, Ohba Y, et al. CalDAG-GEFIII activation of Ras, R-ras, and Rap1. *J Biol Chem* 2000;275:25488-93.
 28. Xu J, Liu M, Yu M, et al. RasGRP1 is a target for VEGF to induce angiogenesis and involved in the endothelial-protective effects of metformin under high glucose in HUVECs. *IUBMB Life* 2019;71:1391-400.
 29. Ottosson-Laakso E, Krus U, Storm P, et al. Glucose-Induced Changes in Gene Expression in Human Pancreatic Islets: Causes or Consequences of Chronic Hyperglycemia. *Diabetes* 2017;66:3013-28.
 30. Jiang H, Liu Y, Qian Y, et al. CHL1 promotes insulin secretion and negatively regulates the proliferation of pancreatic β cells. *Biochem Biophys Res Commun* 2020;525:1095-102.
 31. Li J, Tian M, Hua T, et al. Combination of autophagy and NFE2L2/NRF2 activation as a treatment approach for neuropathic pain. *Autophagy* 2021;17:4062-82.

32. Arsov T, Kelecic J, Frkovic SH, et al. Expanding the clinical spectrum of pathogenic variation in NR2F2: Asplenia. *Eur J Med Genet* 2021;64:104347.
33. Mauri F, Schepkens C, Lapouge G, et al. NR2F2 controls malignant squamous cell carcinoma state by promoting stemness and invasion and repressing differentiation. *Nat Cancer* 2021;2:1152-69.
34. Li W, Zhang Z, Li Y, et al. Abnormal hsa_circ_0003948 expression affects chronic periodontitis development by regulating miR-144-3p/NR2F2/PTEN signaling. *J Periodontol Res* 2022;57:316-23.
35. Wang X, Ding S. The biological and pharmacological connections between diabetes and various types of cancer. *Pathol Res Pract* 2021;227:153641.

(English Language Editor: A. Kassem)

Cite this article as: Huang Y, Cai L, Liu X, Wu Y, Xiang Q, Yu R. Exploring biomarkers and transcriptional factors in type 2 diabetes by comprehensive bioinformatics analysis on RNA-Seq and scRNA-Seq data. *Ann Transl Med* 2022;10(18):1017. doi: 10.21037/atm-22-4303